Importance of protocols for simulation studies in clinical drug development.
about
Optimizing drug development in oncology by clinical trial simulation: Why and how?Statistical challenges in assessing potential efficacy of complex interventions in pilot or feasibility studies.Statistical issues in drug development.Sample size and classification error for Bayesian change-point models with unlabelled sub-groups and incomplete follow-up.Simulation-based sample-sizing and power calculations in logistic regression with partial prior information.Use of statistical and pharmacokinetic-pharmacodynamic modeling and simulation to improve decision-making: A section summary report of the trends and innovations in clinical trial statistics conference.Proposed best practice for projects that involve modelling and simulation.
P2860
Q38675644-714FB331-5D1A-4A41-A8A1-9856C71328E3Q40838999-8BD0FADA-1B54-4F15-B5CC-5EE3DD8F2A0CQ44557252-2207AAD0-B0D5-4F44-AB05-477FF71D2DB4Q47282507-94E18EDF-2A43-4DA6-82D3-E1D5528A75CEQ48372811-7BF766BB-94E5-43FC-B462-E2A88249C873Q50673342-900B9041-CAC5-4F7A-A9A9-334EB5C92036Q52841716-BC607DD0-88AC-44D9-A9D4-B704B78428F8
P2860
Importance of protocols for simulation studies in clinical drug development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Importance of protocols for simulation studies in clinical drug development.
@en
Importance of protocols for simulation studies in clinical drug development.
@nl
type
label
Importance of protocols for simulation studies in clinical drug development.
@en
Importance of protocols for simulation studies in clinical drug development.
@nl
prefLabel
Importance of protocols for simulation studies in clinical drug development.
@en
Importance of protocols for simulation studies in clinical drug development.
@nl
P2860
P356
P1476
Importance of protocols for simulation studies in clinical drug development.
@en
P2093
Andrea Marshall
Mike K Smith
P2860
P304
P356
10.1177/0962280210378949
P577
2010-08-05T00:00:00Z